Correction to: Biologic Drug Quality Assurance to Optimize HER2+ Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3.
Journal
Targeted oncology
ISSN: 1776-260X
Titre abrégé: Target Oncol
Pays: France
ID NLM: 101270595
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
pubmed:
21
10
2020
medline:
21
10
2020
entrez:
20
10
2020
Statut:
ppublish
Résumé
The article Biologic Drug Quality Assurance to Optimize HER2+ Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3.
Identifiants
pubmed: 33079308
doi: 10.1007/s11523-020-00761-7
pii: 10.1007/s11523-020-00761-7
pmc: PMC7852897
doi:
Types de publication
Published Erratum
Langues
eng
Sous-ensembles de citation
IM
Pagination
805Commentaires et corrections
Type : ErratumFor